P53: Pro-aging or pro-longevity?

Aging

Volumn 2, Issue 7, 2010, Pages 377-379

  de Keizer, Peter L J ^a   Laberge, Rémi Martin ^a   Campisi, Judith ^a,b  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AGING; APOPTOSIS; CELL AGING; DNA REPAIR; EDITORIAL; GENETICS; HUMAN; LONGEVITY; PHYSIOLOGY;

AGING; APOPTOSIS; CELL AGING; DNA REPAIR; HUMANS; LONGEVITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79951855526     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100178     Document Type: Editorial

References (30)

1. De Leo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of atransformation-related antigen in chemically induced sarcomas and other transformedcells of the mouse. Proc Natl Acad Sci USA 1979; 76: 2420-2424.
2. Crawford LV, Pim DC, Gurney EG, Goodfellow P, Taylor- Papadimitriou J. Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. Proc Natl Acad Sci USA 1981; 78: 41-45.
3. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-1093.
4. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990; 4: 1-8.
5. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nature Rev Cancer 2009; 9: 724-737.
6. Chipuk JE, Green DR. Cytoplasmic p53: bax and forward. Cell Cycle 2004; 3: 429-431.
7. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
8. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Ingelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty G, Bradley A, Donehower L. p53 mutant mice that display early aging-associated phenotypes. Nature 2002; 415: 45-53.
9. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrable H. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004; 18: 306-319.
10. Campisi J. Between Scylla and Charybdis: p53 links tumor suppression and aging. Mech Ageing Dev 2002; 123: 567-573.
11. Campisi J. Fragile fugue: p53 in aging, cancer and IGF signaling. Nature Med 2004; 10: 231-232.
12. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA, Serrano M. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002; 21: 6225-6235.
13. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Viña J, Blasco MA, Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007; 448: 375-379.
14. Kenyon CJ. The genetics of ageing. Nature 2010; 464: 504- 512.
15. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2001; 27: 462-467.
16. Salminen A, Kaarniranta K. Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal 2010; 22: 573-577.
17. Tomás-Loba A, Flores I, Fernández-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borrás C, Matheu A, Klatt P, Flores JM, Viña J, Serrano M, Blasco MA. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 2008; 135: 609-622.
18. Gatza CE, Dumble M, Kittrell F, Edwards DG, Dearth RK, Lee AV, Xu J, Medina D, Donehower LA. Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. Dev Biol 2008; 313: 130-141.
19. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
20. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22: 4212-4222.
21. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nature Rev Molec Cell Biol 2007; 8: 729-740.
22. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz D, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell non-automous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853-2868.
23. Coppe JP, Patil CK, Rodier F, Krtolica A, Beausejour C, Parrinello S, Hodgson G, Chin K, Desprez PY, Campisi J. A humanike senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS ONE 2010; 5: e9188.
24. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescenceassociated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010; 5: 99-118.
25. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010; 29: 273-283.
26. Ferrucci L, Ble A, Bandinelli S, Lauretani F, Suthers K, Guralnik JM. A flame burning within. Aging Clin Exp Res 2004; 16: 240-243.
27. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev 2007; 65: 173-176.
28. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna- Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 2007; 128: 83-91.
29. Bruunsgaard H. The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality. Dan Med Bull 2006; 53: 285-309.
30. Freund A, Orjalo A, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Molec Med 2010; 16: 238-248.